{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T03:41:09Z","timestamp":1793677269570,"version":"4.5.1"},"reference-count":116,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.jaad.2020.03.132","type":"journal-article","created":{"date-parts":[[2020,5,23]],"date-time":"2020-05-23T02:22:11Z","timestamp":1590200531000},"page":"1255-1268","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":464,"title":["Immune checkpoint inhibitor\u2013related dermatologic adverse events"],"prefix":"10.1016","volume":"83","author":[{"given":"Amaris N.","family":"Geisler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory S.","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dulce M.","family":"Barrios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald Y.M.","family":"Leung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea P.","family":"Moy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey A.","family":"Kern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario E.","family":"Lacouture","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2020.03.132_bib1","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","article-title":"Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group","volume":"5","author":"Puzanov","year":"2017","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jaad.2020.03.132_bib2","doi-asserted-by":"crossref","first-page":"405","DOI":"10.5301\/tj.5000625","article-title":"Pathogenesis, clinical manifestations and management of immune checkpoint inhibitors toxicity","volume":"103","author":"Inno","year":"2017","journal-title":"Tumori"},{"key":"10.1016\/j.jaad.2020.03.132_bib3","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1001\/jamaoncol.2017.2391","article-title":"Measuring toxic effects and time to treatment failure for nivolumab plus ipilimumab in melanoma","volume":"4","author":"Shoushtari","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jaad.2020.03.132_bib4","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jaad.2020.03.132_bib5","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jaad.2014.02.035","article-title":"Ipilimumab in patients with cancer and the management of dermatologic adverse events","volume":"71","author":"Lacouture","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2020.03.132_bib6","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1002\/cncr.27969","article-title":"Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced melanoma","volume":"119","author":"Weber","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.jaad.2020.03.132_bib7","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1097\/CCO.0000000000000290","article-title":"Dermatologic complications of anti-PD-1\/PD-L1 immune checkpoint antibodies","volume":"28","author":"Sibaud","year":"2016","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.jaad.2020.03.132_bib8","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s40257-017-0336-3","article-title":"Dermatologic reactions to immune checkpoint inhibitors: skin toxicities and immunotherapy","volume":"19","author":"Sibaud","year":"2018","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.jaad.2020.03.132_bib9","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ctrv.2016.02.003","article-title":"Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy","volume":"45","author":"Eigentler","year":"2016","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.jaad.2020.03.132_bib10","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1093\/annonc\/mdv623","article-title":"Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper","volume":"27","author":"Champiat","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jaad.2020.03.132_bib11","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.2217\/imt-2016-0074","article-title":"Dermatologic adverse events of checkpoint inhibitors: what an oncologist should know","volume":"8","author":"Habre","year":"2016","journal-title":"Immunotherapy"},{"key":"10.1016\/j.jaad.2020.03.132_bib12","doi-asserted-by":"crossref","DOI":"10.1177\/1758835918764628","article-title":"Clinical assessment of immune-related adverse events","volume":"10","author":"Sosa","year":"2018","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.jaad.2020.03.132_bib13","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ctrv.2016.02.001","article-title":"Management of toxicities of immune checkpoint inhibitors","volume":"44","author":"Spain","year":"2016","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.jaad.2020.03.132_bib14","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.currproblcancer.2016.12.001","article-title":"Cutaneous adverse effects of the immune checkpoint inhibitors","volume":"41","author":"Collins","year":"2017","journal-title":"Curr Probl Cancer"},{"key":"10.1016\/j.jaad.2020.03.132_bib15","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/nrclinonc.2016.58","article-title":"Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination","volume":"13","author":"Boutros","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jaad.2020.03.132_bib16","first-page":"560","article-title":"Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities","volume":"4","author":"Villadolid","year":"2015","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.jaad.2020.03.132_bib17","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1158\/1078-0432.CCR-15-1136","article-title":"Nivolumab in resected and unresectable metastatic melanoma: characteristics of immune-related adverse events and association with outcomes","volume":"22","author":"Freeman-Keller","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jaad.2020.03.132_bib18","doi-asserted-by":"crossref","first-page":"6043","DOI":"10.1200\/JCO.2005.06.205","article-title":"Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4","volume":"23","author":"Attia","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2020.03.132_bib19","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1001\/jamaoncol.2015.2274","article-title":"Prognostic significance of cutaneous adverse events associated with pembrolizumab therapy","volume":"1","author":"Lo","year":"2015","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jaad.2020.03.132_bib20","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S1470-2045(09)70334-1","article-title":"Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study","volume":"11","author":"Wolchok","year":"2010","journal-title":"Lancet Oncol"},{"issue":"suppl 6","key":"10.1016\/j.jaad.2020.03.132_bib21","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1093\/annonc\/mdw379.01","article-title":"Overall survival (OS) and safety results from a phase 3 trial of ipilimumab (IPI) at 3 mg\/kg vs 10 mg\/kg in patients with metastatic melanoma (MEL)","volume":"27","author":"Ascierto","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jaad.2020.03.132_bib22","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1801946","article-title":"Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden","volume":"378","author":"Hellmann","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2020.03.132_bib23","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(16)30624-6","article-title":"Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study","volume":"18","author":"Hellmann","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jaad.2020.03.132_bib24","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1634\/theoncologist.2017-0133","article-title":"Immune-related adverse events as a biomarker in non-melanoma patients treated with programmed cell death 1 inhibitors","volume":"22","author":"Judd","year":"2017","journal-title":"Oncologist"},{"key":"10.1016\/j.jaad.2020.03.132_bib25","doi-asserted-by":"crossref","first-page":"3815","DOI":"10.1200\/JCO.2016.72.1167","article-title":"Pooled analysis safety profile of nivolumab and ipilimumab combination therapy in patients with advanced melanoma","volume":"35","author":"Sznol","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2020.03.132_bib26","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1200\/JCO.2015.66.1389","article-title":"Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma","volume":"35","author":"Weber","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2020.03.132_bib27","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.cllc.2018.10.002","article-title":"Association between immune-related adverse events and efficacy of immune checkpoint inhibitors in non-small-cell lung cancer","volume":"20","author":"Grangeon","year":"2019","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.jaad.2020.03.132_bib28","doi-asserted-by":"crossref","first-page":"4550","DOI":"10.1158\/1078-0432.CCR-15-2569","article-title":"Molecular pathways: immune checkpoint antibodies and their toxicities","volume":"22","author":"Cousin","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jaad.2020.03.132_bib29","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1001\/jamaoncol.2016.1051","article-title":"Treatment of the immune-related adverse effects of immune checkpoint inhibitors: a review","volume":"2","author":"Friedman","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jaad.2020.03.132_bib30","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1053\/j.seminoncol.2019.10.003","article-title":"A systematic review on the emerging association between the occurrence of immune-related adverse events and clinical outcomes with checkpoint inhibitors in advanced cancer patients","volume":"46","author":"Cortellini","year":"2019","journal-title":"Semin Oncol"},{"key":"10.1016\/j.jaad.2020.03.132_bib31","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1186\/s40425-019-0805-8","article-title":"Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors","volume":"7","author":"Das","year":"2019","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jaad.2020.03.132_bib32","doi-asserted-by":"crossref","first-page":"e121","DOI":"10.1016\/j.jaad.2012.12.963","article-title":"The risk of rash associated with ipilimumab in patients with cancer: a systematic review of the literature and meta-analysis","volume":"69","author":"Minkis","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2020.03.132_bib33","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/j.jaad.2018.10.062","article-title":"Inflammatory eruptions associated with immune checkpoint inhibitor therapy: a single-institution retrospective analysis with stratification of reactions by toxicity and implications for management","volume":"80","author":"Coleman","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2020.03.132_bib34","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3389\/fphar.2017.00049","article-title":"Current diagnosis and management of immune related adverse events (irAEs) induced by immune checkpoint inhibitor therapy","volume":"8","author":"Kumar","year":"2017","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jaad.2020.03.132_bib35","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1200\/JCO.19.00189","article-title":"Immune checkpoint inhibitor outcomes for patients with non-small-cell lung cancer receiving baseline corticosteroids for palliative versus nonpalliative indications","volume":"37","author":"Ricciuti","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2020.03.132_bib36","doi-asserted-by":"crossref","first-page":"3706","DOI":"10.1002\/cncr.31629","article-title":"High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanoma","volume":"124","author":"Faje","year":"2018","journal-title":"Cancer"},{"key":"10.1016\/j.jaad.2020.03.132_bib37","doi-asserted-by":"crossref","first-page":"e000477","DOI":"10.1136\/esmoopen-2018-000477","article-title":"Early use of steroids affects immune cells and impairs immunotherapy efficacy","volume":"4","author":"Della Corte","year":"2019","journal-title":"ESMO Open"},{"key":"10.1016\/j.jaad.2020.03.132_bib38","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1200\/JCO.2018.79.0006","article-title":"Impact of baseline\u00a0steroids on efficacy of programmed cell death-1 and programmed death-ligand 1 blockade in patients with\u00a0non-small-cell lung cancer","volume":"36","author":"Arbour","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2020.03.132_bib39","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.1200\/JCO.2015.60.8448","article-title":"Immune-related adverse\u00a0events, need for systemic immunosuppression, and\u00a0effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at Memorial Sloan Kettering Cancer Center","volume":"33","author":"Horvat","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2020.03.132_bib40","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ejca.2015.11.016","article-title":"Immune-related adverse events with immune checkpoint blockade: a comprehensive review","volume":"54","author":"Michot","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jaad.2020.03.132_bib41","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1093\/annonc\/mdx286","article-title":"Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review","volume":"28","author":"Khoja","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jaad.2020.03.132_bib42","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1080\/21645515.2017.1322241","article-title":"A new frontier in treatment of advanced melanoma: redefining clinical management in the era of immune checkpoint inhibitors","volume":"13","author":"Levine","year":"2017","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.jaad.2020.03.132_bib43","doi-asserted-by":"crossref","first-page":"8372","DOI":"10.1073\/pnas.1533209100","article-title":"Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma","volume":"100","author":"Phan","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jaad.2020.03.132_bib44","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1001\/jamadermatol.2015.1916","article-title":"Pembrolizumab cutaneous adverse events and their association with disease progression","volume":"151","author":"Sanlorenzo","year":"2015","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaad.2020.03.132_bib45","doi-asserted-by":"crossref","first-page":"5288","DOI":"10.1158\/0008-5472.CAN-16-0194","article-title":"Assessing immune-related adverse events of efficacious combination immunotherapies in preclinical models of cancer","volume":"76","author":"Liu","year":"2016","journal-title":"Cancer Res"},{"key":"10.1016\/j.jaad.2020.03.132_bib46","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1158\/0008-5472.CAN-16-2324","article-title":"Immune toxicities elicted by CTLA-4 blockade in cancer patients are associated with early diversification of the T-cell repertoire","volume":"77","author":"Oh","year":"2017","journal-title":"Cancer Res"},{"key":"10.1016\/j.jaad.2020.03.132_bib47","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1158\/2326-6066.CIR-17-0755","article-title":"Safety and efficacy of re-treating with immunotherapy after immune-related adverse events in patients with NSCLC","volume":"6","author":"Santini","year":"2018","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.jaad.2020.03.132_bib48","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/cup.12858","article-title":"Diverse types of dermatologic toxicities from immune checkpoint blockade therapy","volume":"44","author":"Curry","year":"2017","journal-title":"J Cutan Pathol"},{"key":"10.1016\/j.jaad.2020.03.132_bib49","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1200\/JCO.2012.41.6750","article-title":"Management of immune-related adverse events and kinetics of response with ipilimumab","volume":"30","author":"Weber","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2020.03.132_bib50","doi-asserted-by":"crossref","first-page":"76","DOI":"10.14694\/EdBook_AM.2015.35.76","article-title":"Managing immune checkpoint-blocking antibody side effects","author":"Postow","year":"2015","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.jaad.2020.03.132_bib51","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s11864-016-0434-0","article-title":"Cutaneous complications of targeted melanoma therapy","volume":"17","author":"de Golian","year":"2016","journal-title":"Curr Treat Options Oncol"},{"key":"10.1016\/j.jaad.2020.03.132_bib52","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1001\/archderm.142.2.166","article-title":"Skin reactions in a subset of patients with stage IV melanoma treated with anti-cytotoxic T-lymphocyte antigen 4 monoclonal antibody as a single agent","volume":"142","author":"Jaber","year":"2006","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2020.03.132_bib53","doi-asserted-by":"crossref","first-page":"2746","DOI":"10.1200\/JCO.18.02141","article-title":"Treatment outcomes of immune-related cutaneous adverse events","volume":"37","author":"Phillips","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2020.03.132_bib54","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.jaad.2018.05.035","article-title":"Characterization of dermatitis after PD-1\/PD-L1 inhibitor therapy and association with multiple oncologic outcomes: a retrospective case-control study","volume":"79","author":"Min Lee","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2020.03.132_bib55","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1097\/PAS.0000000000000900","article-title":"Cutaneous eruptions in patients receiving immune checkpoint blockade: clinicopathologic analysis of the nonlichenoid histologic pattern","volume":"41","author":"Kaunitz","year":"2017","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.jaad.2020.03.132_bib56","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1097\/DAD.0000000000000688","article-title":"Lichenoid dermatologic toxicity from immune checkpoint blockade therapy: a detailed examination of the clinicopathologic features","volume":"39","author":"Tetzlaff","year":"2017","journal-title":"Am J Dermatopathol"},{"key":"10.1016\/j.jaad.2020.03.132_bib57","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1001\/jamadermatol.2016.2226","article-title":"Clinical and histologic features of lichenoid mucocutaneous eruptions due to anti-programmed cell death 1 and anti-programmed cell death ligand 1 immunotherapy","volume":"152","author":"Shi","year":"2016","journal-title":"JAMA Dermatol"},{"issue":"suppl 1","key":"10.1016\/j.jaad.2020.03.132_bib58","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s40257-018-0384-3","article-title":"Toxic side effects of targeted therapies and immunotherapies affecting the skin, oral mucosa, hair, and nails","volume":"19","author":"Lacouture","year":"2018","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.jaad.2020.03.132_bib59","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1111\/cup.12666","article-title":"Immunohistochemical analysis of lichenoid reactions in patients treated with anti-PD-L1 and anti-PD-1 therapy","volume":"43","author":"Schaberg","year":"2016","journal-title":"J Cutan Pathol"},{"key":"10.1016\/j.jaad.2020.03.132_bib60","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1634\/theoncologist.2018-0128","article-title":"A case of nivolumab-induced bullous pemphigoid: review of dermatologic toxicity associated with programmed cell death protein-1\/programmed death ligand-1 inhibitors and recommendations for diagnosis and management","volume":"23","author":"Lopez","year":"2018","journal-title":"Oncologist"},{"key":"10.1016\/j.jaad.2020.03.132_bib61","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1111\/ijd.13984","article-title":"A review of bullous pemphigoid associated with PD-1 and PD-L1 inhibitors","volume":"57","author":"Lopez","year":"2018","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jaad.2020.03.132_bib62","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.jaad.2018.07.008","article-title":"Bullous disorders associated with anti-PD-1 and anti-PD-L1 therapy: a retrospective analysis evaluating the clinical and histopathologic features, frequency, and impact on cancer therapy","volume":"79","author":"Siegel","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2020.03.132_bib63","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1158\/2326-6066.CIR-15-0123","article-title":"Autoimmune bullous skin disorders with immune checkpoint inhibitors targeting PD-1 and PD-L1","volume":"4","author":"Naidoo","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.jaad.2020.03.132_bib64","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1001\/jamadermatol.2017.0091","article-title":"Rituximab treatment of nivolumab-induced bullous pemphigoid","volume":"153","author":"Sowerby","year":"2017","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaad.2020.03.132_bib65","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1001\/jamadermatol.2018.4560","article-title":"Clinical characterization of immunotherapy-related pruritus among patients seen in 2 oncodermatology clinics","volume":"155","author":"Phillips","year":"2019","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaad.2020.03.132_bib66","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/S1470-2045(12)70373-X","article-title":"Aprepitant for management of severe pruritus related to biological cancer treatments: a pilot study","volume":"13","author":"Santini","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jaad.2020.03.132_bib67","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1001\/jamadermatol.2015.2707","article-title":"Association of vitiligo with tumor response in patients with metastatic melanoma treated with pembrolizumab","volume":"152","author":"Hua","year":"2016","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaad.2020.03.132_bib68","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1200\/JCO.2014.57.4756","article-title":"Vitiligo-like depigmentation in patients with stage III-IV melanoma receiving immunotherapy and its association with survival: a systematic review and meta-analysis","volume":"33","author":"Teulings","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2020.03.132_bib69","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1093\/annonc\/mdp325","article-title":"Vitiligo is an independent favourable prognostic factor in stage III and IV metastatic melanoma patients: results from a single-institution hospital-based observational cohort study","volume":"21","author":"Quaglino","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jaad.2020.03.132_bib70","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ejca.2016.02.010","article-title":"Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor","volume":"60","author":"Belum","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jaad.2020.03.132_bib71","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.jaad.2016.10.044","article-title":"Vitiligo-like lesions occurring in patients receiving anti-programmed cell death-1 therapies are clinically and biologically distinct from vitiligo","volume":"76","author":"Larsabal","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2020.03.132_bib72","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1111\/ced.13867","article-title":"Vitiligo-like depigmentation in oncology patients treated with immunotherapies for nonmelanoma metastatic cancers","volume":"44","author":"Liu","year":"2019","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jaad.2020.03.132_bib73","doi-asserted-by":"crossref","first-page":"e13810","DOI":"10.1097\/MD.0000000000013810","article-title":"Vitiligo-like lesions in a patient treated with nivolumab for renal cell carcinoma","volume":"97","author":"Lolli","year":"2018","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.jaad.2020.03.132_bib74","doi-asserted-by":"crossref","first-page":"e1231292","DOI":"10.1080\/2162402X.2016.1231292","article-title":"Characterization of nivolumab-associated skin reactions in patients with metastatic non-small cell lung cancer","volume":"5","author":"Hasan Ali","year":"2016","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.jaad.2020.03.132_bib75","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/S1470-2045(16)30098-5","article-title":"Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1\/2 trial","volume":"17","author":"Antonia","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jaad.2020.03.132_bib76","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2020.03.132_bib77","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1200\/JCO.2009.26.7609","article-title":"Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates","volume":"28","author":"Brahmer","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2020.03.132_bib78","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2020.03.132_bib79","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the treatment of non-small-cell lung cancer","volume":"372","author":"Garon","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2020.03.132_bib80","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S1470-2045(16)30053-5","article-title":"Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial","volume":"17","author":"Goldberg","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jaad.2020.03.132_bib81","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","article-title":"Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial","volume":"387","author":"Herbst","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jaad.2020.03.132_bib82","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1016\/S1470-2045(16)30498-3","article-title":"Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study","volume":"17","author":"Langer","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jaad.2020.03.132_bib83","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1111\/cas.13932","article-title":"KEYNOTE-025: phase 1b study of pembrolizumab in Japanese patients with previously treated programmed death ligand 1-positive advanced non-small-cell lung cancer","volume":"110","author":"Nishio","year":"2019","journal-title":"Cancer Sci"},{"key":"10.1016\/j.jaad.2020.03.132_bib84","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1056\/NEJMoa1810865","article-title":"Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer","volume":"379","author":"Paz-Ares","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2020.03.132_bib85","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2020.03.132_bib86","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1200\/JCO.2016.66.9861","article-title":"Nivolumab in combination with platinum-based doublet chemotherapy for first-line treatment of advanced non-small-cell lung cancer","volume":"34","author":"Rizvi","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2020.03.132_bib87","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1016\/j.jdcr.2018.08.009","article-title":"Vitiligo in a patient undergoing nivolumab treatment for non-small cell lung cancer","volume":"4","author":"Kosche","year":"2018","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.jaad.2020.03.132_bib88","doi-asserted-by":"crossref","first-page":"E481","DOI":"10.21037\/jtd.2018.05.104","article-title":"Nivolumab induced vitiligo-like lesions in a patient with metastatic squamous cell carcinoma of the lung","volume":"10","author":"Nishino","year":"2018","journal-title":"J Thorac Dis"},{"key":"10.1016\/j.jaad.2020.03.132_bib89","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.lungcan.2017.04.019","article-title":"Vitiligo in a patient with lung adenocarcinoma treated with nivolumab: a case report","volume":"109","author":"Uenami","year":"2017","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jaad.2020.03.132_bib90","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.jdcr.2016.10.008","article-title":"Nivolumab-associated vitiligo-like depigmentation in a patient with acute myeloid leukemia: a novel finding","volume":"3","author":"Yin","year":"2017","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.jaad.2020.03.132_bib91","first-page":"283","article-title":"Immunotherapy \u201cshock\u201d with vitiligo due to nivolumab administration as third line therapy in lung adenocarcinoma","volume":"22","author":"Zarogoulidis","year":"2017","journal-title":"Respir Med Case Rep"},{"key":"10.1016\/j.jaad.2020.03.132_bib92","doi-asserted-by":"crossref","first-page":"183","DOI":"10.24920\/31805","article-title":"Treatment of skin reaction induced by nivolumab combined with radiotherapy in non-small cell lung cancer: a case report","volume":"33","author":"Zhao","year":"2018","journal-title":"Chin Med Sci J"},{"key":"10.1016\/j.jaad.2020.03.132_bib93","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1111\/ced.13382","article-title":"Vitiligo-like lesions and immune checkpoint inhibition therapy: is it truly an adverse event exclusive to patients with melanoma?","volume":"43","author":"Rodriguez-Lomba","year":"2018","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jaad.2020.03.132_bib94","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1159\/000492666","article-title":"Nivolumab-induced impressive response of refractory pulmonary sarcomatoid carcinoma with brain metastasis","volume":"11","author":"Salati","year":"2018","journal-title":"Case Rep Oncol"},{"key":"10.1016\/j.jaad.2020.03.132_bib95","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1001\/jamaoncol.2018.0186","article-title":"Hypopigmented skin lesions after immunotherapy","volume":"4","author":"Dumbrava","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jaad.2020.03.132_bib96","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/S1470-2045(18)30081-0","article-title":"Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial","volume":"19","author":"Atkins","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jaad.2020.03.132_bib97","doi-asserted-by":"crossref","first-page":"3851","DOI":"10.1200\/JCO.2016.72.1985","article-title":"Safety and efficacy of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma: the CheckMate 016 study","volume":"35","author":"Hammers","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2020.03.132_bib98","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Motzer","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2020.03.132_bib99","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1200\/JCO.2014.59.0703","article-title":"Nivolumab for metastatic renal cell carcinoma: results of a randomized phase II trial","volume":"33","author":"Motzer","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2020.03.132_bib100","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2020.03.132_bib101","doi-asserted-by":"crossref","first-page":"259","DOI":"10.2340\/00015555-2212","article-title":"Exacerbation of psoriasis during nivolumab therapy for metastatic melanoma","volume":"96","author":"Matsumura","year":"2016","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaad.2020.03.132_bib102","doi-asserted-by":"crossref","first-page":"e89","DOI":"10.1111\/jdv.13336","article-title":"Exacerbation of psoriasis vulgaris during nivolumab for oral mucosal melanoma","volume":"30","author":"Kato","year":"2016","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2020.03.132_bib103","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1001\/jamadermatol.2015.0249","article-title":"Occurrence of psoriasiform eruption during nivolumab therapy for primary oral mucosal melanoma","volume":"151","author":"Ohtsuka","year":"2015","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaad.2020.03.132_bib104","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1001\/jamadermatol.2015.5210","article-title":"Inverse psoriasiform eruption during pembrolizumab therapy for metastatic melanoma","volume":"152","author":"Totonchy","year":"2016","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaad.2020.03.132_bib105","doi-asserted-by":"crossref","first-page":"e254","DOI":"10.1111\/jdv.14011","article-title":"Anti-PD1-induced psoriasis: a study of 21 patients","volume":"31","author":"Bonigen","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2020.03.132_bib106","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.2147\/CMAR.S163391","article-title":"Severe cutaneous adverse reactions induced by targeted anticancer therapies and immunotherapies","volume":"10","author":"Chen","year":"2018","journal-title":"Cancer Manag Res"},{"key":"10.1016\/j.jaad.2020.03.132_bib107","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/cup.12876","article-title":"Epidermal programmed cell death-ligand 1 expression in TEN associated with nivolumab therapy","volume":"44","author":"Vivar","year":"2017","journal-title":"J Cutan Pathol"},{"key":"10.1016\/j.jaad.2020.03.132_bib108","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1097\/CJI.0000000000000112","article-title":"Toxic epidermal necrolysis-like reaction with severe satellite cell necrosis associated with nivolumab in a patient with ipilimumab refractory metastatic melanoma","volume":"39","author":"Nayar","year":"2016","journal-title":"J Immunother"},{"key":"10.1016\/j.jaad.2020.03.132_bib109","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.ejca.2017.03.026","article-title":"Pembrolizumab-induced Stevens-Johnson syndrome in non-melanoma patients","volume":"81","author":"Saw","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jaad.2020.03.132_bib110","doi-asserted-by":"crossref","first-page":"4023","DOI":"10.1158\/1078-0432.CCR-15-2872","article-title":"Cytotoxic cutaneous adverse drug reactions during anti-PD-1 therapy","volume":"22","author":"Goldinger","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jaad.2020.03.132_bib111","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1111\/bjd.15237","article-title":"Immune-related alopecia\u00a0(areata and universalis) in cancer patients receiving\u00a0immune checkpoint inhibitors","volume":"176","author":"Zarbo","year":"2017","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2020.03.132_bib112","article-title":"PD-1 inhibitor induced alopecia areata","volume":"24","author":"Guidry","year":"2018","journal-title":"Dermatol Online J"},{"key":"10.1016\/j.jaad.2020.03.132_bib113","first-page":"1","article-title":"Oral health in oncology: impact of immunotherapy","volume":"23","author":"Jackson","year":"2015","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.jaad.2020.03.132_bib114","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1200\/JCO.2013.53.0105","article-title":"Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab","volume":"32","author":"Topalian","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2020.03.132_bib115","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1038\/s41586-019-1162-y","article-title":"Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy","volume":"569","author":"Perez-Ruiz","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.jaad.2020.03.132_bib116","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.3389\/fphar.2019.01173","article-title":"Adverse events of concurrent immune checkpoint inhibitors and antiangiogenic agents: a systematic review","volume":"10","author":"Gao","year":"2019","journal-title":"Front Pharmacol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962220309634?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962220309634?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:54:42Z","timestamp":1759272882000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962220309634"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":116,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["S0190962220309634"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2020.03.132","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immune checkpoint inhibitor\u2013related dermatologic adverse events","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2020.03.132","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/S0190-9622(20)32509-3","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}